OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Nitric oxide (NO) is a ubiquitous signaling molecule with complex, context-dependent roles in human physiology. Dysregulated NO production contributes to the progression of various diseases, notably affecting women’s health in areas such as pregnancy, autoimmune disorders, cardiovascular conditions, endometriosis, chronic pain, and postmenopausal complications. Despite its therapeutic potential, drug development targeting the NO pathway remains challenging due to its pleiotropic effects and systemic nature.
Our research focuses on harnessing the therapeutic potential of NO through precise and controlled modulation. We are developing stimuli-responsive NO donors and novel peptides that selectively inhibit inducible nitric oxide synthase (iNOS) in a targeted manner. This approach aims to deliver tissue-specific therapeutic effects, minimizing systemic side effects and addressing the limitations of current NO-modulating therapies.
